Kurume University
Research Center for Innovative Cancer Therapy
Director
Research theme for competitive and other funds (23):
2024 - 2027 Development of aptamers targeting cell adhesion factors characteristically highly expressed in "combined hepatocellular-cholangiocarcinoma" and evaluation of their anti-tumour effects
Toru Nakamura, Atsutaka Masuda, Makoto Kako, Hirayuki Enomoto, Masaki Kaibori, Yasuyuki Fujita, Kyoko Tanizawa, Tetsuya Ioji, Yoshihiro Fujimori, Kei Fukami, et al. Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial. Regenerative therapy. 2024. 27. 455-463
Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda. Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study". Liver cancer. 2024. 13. 6. 671-673
Hiroyuki Suzuki, Michitaka Fukuda, Tomotake Shirono, Reiichiro Kondo, Toshimitsu Tanaka, Takashi Niizeki, Jun Akiba, Hironori Koga, Takumi Kawaguchi. A Rare Case of Primary Hepatic Undifferentiated Pleomorphic Sarcoma: Exploring Cancer-related Gene Mutations. Internal medicine (Tokyo, Japan). 2024
Takahiko Sakaue, Kalpana Deepa Priya Dorayappan, Roman Zingarelli, Wafa Khadraoui, Muralidharan Anbalagan, John Wallbillich, Balazs Bognar, Ross Wanner, Casey Cosgrove, Adrian Suarez, et al. Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin. Oncogene. 2024. 43. 49. 3586-3597
Etsuko Moriyama, Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, Masatoshi Tanaka, Tomotake Shirono, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, et al. Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. Current oncology (Toronto, Ont.). 2024. 31. 10. 5821-5831
Mitsuhiko Abe, Takafumi Yoshida, Jun Akiba, Yu Ikezono, Fumitaka Wada, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Hideki Iwamoto, Toru Nakamura, et al. STAT3 deficiency prevents hepatocarcinogenesis and promotes transdifferentiation of hepatocytes into biliary cells in chronic liver injury of mice. HEPATOLOGY. 2017. 66. 718A-718A
Koga H. TCF-4 isoform upregulates CLAUDIN-2, therapy activating NOTCH signaling in human liver cancer cells. Research Report 2015. 2016
Koga H, Ikezono Y, Torimura T. Pancreatic DCLK1 marks quiescent but oncogenic progenitors: a possible link to neuroendocrine tumors. Stem Cell Investig. 2016. 3. 37(page 1-2)
Involvement of p21WAF1/Cip1 and p27Kip1 in troglitazone-induced cell-cycle arrest in human hepatoma cell lines
Frontier in Hepatology Springer-Verlag Tokyo 2002
American Association for the Study of Liver Diseases (AASLD)
, American Association for Cancer Research (AACR)
, 日本臨床分子形態学会(旧 日本臨床電子顕微鏡学会)
, 日本内視鏡学会
, 日本癌学会
, 日本肝臓学会
, 日本消化器病学会
, 日本内科学会